BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)

BioMarin's (BMRN) Pegvaliase Likely to Receive FDA Approval Amid Recent Mixed Data - Wedbush

March 22, 2016 6:32 AM EDT

Wedbush reaffirms BioMarin Pharmaceuticals (Nasdaq: BMRN) at Neutral with a price target of $108 after the company reported that the Phase 3... More

Leerink Partners Reiterates Outperform on BioMarin Pharma (BMRN) Following Mixed Ph. 3 Data Results

March 21, 2016 1:17 PM EDT

Leerink Partners reiterated an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's mixed PEG-PAL Ph. 3 data. In study '302, blood Phe elevated to near-baseline levels (1385.7 uM) upon discontinuation vs. pts. continuing PEG-PAL treatment (527.2 uM) (p... More